Collaborative Fund Advisors LLC Acquires Shares of 3,293 Neurocrine Biosciences, Inc. $NBIX

Collaborative Fund Advisors LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,293 shares of the company’s stock, valued at approximately $434,000.

Several other institutional investors have also modified their holdings of the company. Huntington National Bank raised its stake in Neurocrine Biosciences by 12.6% in the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after buying an additional 76 shares in the last quarter. Perigon Wealth Management LLC boosted its position in shares of Neurocrine Biosciences by 3.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after acquiring an additional 78 shares in the last quarter. Motley Fool Asset Management LLC increased its holdings in shares of Neurocrine Biosciences by 4.8% in the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after acquiring an additional 78 shares during the last quarter. Main Management ETF Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock valued at $1,111,000 after acquiring an additional 80 shares during the last quarter. Finally, Signaturefd LLC raised its position in shares of Neurocrine Biosciences by 4.5% during the 4th quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock worth $273,000 after acquiring an additional 83 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $174.26 on Monday. The stock has a fifty day moving average price of $155.99 and a 200 day moving average price of $141.73. The stock has a market cap of $17.52 billion, a PE ratio of 26.85, a P/E/G ratio of 0.69 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $174.38.

Insiders Place Their Bets

In other news, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction on Monday, June 1st. The stock was sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the completion of the transaction, the insider owned 25,846 shares of the company’s stock, valued at $4,141,821.50. The trade was a 29.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the sale, the director owned 34,480 shares in the company, valued at $5,435,772. This represents a 30.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 365,234 shares of company stock valued at $57,031,540. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Morgan Stanley lifted their price objective on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Wedbush upped their price objective on Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Leerink Partners raised their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Finally, Piper Sandler boosted their target price on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $187.52.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.